Lung cancer

Zykadia Approved for First-Line ALK-Positive Metastatic NSCLC

By May 30, 2017

The FDA approval was based on data from the Phase 3, open-label, randomized, multicenter, global ASCEND-4 trial.

Noninvasive Biomarker May ID Lung Cancer

February 28, 2017

Simple technique is based on cancer DNA and seems accurate for use after chest CT scan, researchers say

New Pemetrexed Formulation to Be Reviewed by FDA

By January 03, 2017

The NDA proposes the use of ready-to-dilute pemetrexed injection for the treatment of locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and mesothelioma (in combination with cisplatin).

Xalkori Approved for ROS1-Positive Metastatic NSCLC

By March 11, 2016

The FDA has approved Xalkori (crizotinib capsules; Pfizer) for the treatment of metastatic non-small cell lung cancer (NSCLC) in patients whose tumors are ROS1-positive.

FDA Approves Tagrisso to Treat Non-Small Cell Lung Cancer

November 13, 2015

The US Food and Drug Administration (FDA) has approved Tagrisso (osimertinib; AstraZeneca) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.